Bank of New York Mellon Corp Takes $339.03 Million Position in Boston Scientific Corporation $BSX

Bank of New York Mellon Corp acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 7,943,553 shares of the medical equipment provider’s stock, valued at approximately $339,031,000.

Other hedge funds have also recently bought and sold shares of the company. Focus Partners Advisor Solutions LLC acquired a new stake in Boston Scientific in the 2nd quarter worth approximately $1,355,000. State of Wyoming acquired a new position in Boston Scientific during the 2nd quarter worth $42,000. ABN AMRO Bank N.V. acquired a new position in Boston Scientific during the 2nd quarter worth $372,000. S&CO Inc. bought a new stake in Boston Scientific during the second quarter valued at about $7,246,000. Finally, Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific in the second quarter valued at about $25,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Michael F. Mahoney bought 186,240 shares of Boston Scientific stock in a transaction on Monday, August 3rd. The shares were bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have acquired 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BSX. Piper Sandler reiterated an “overweight” rating and set a $65.00 price target on shares of Boston Scientific in a report on Friday, June 12th. Truist Financial cut their target price on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Wells Fargo & Company cut their price objective on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a research report on Thursday, July 30th. Finally, Barclays reduced their target price on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research note on Thursday, May 28th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Price Performance

Shares of BSX stock opened at $50.39 on Friday. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The firm’s 50 day moving average is $46.34 and its 200-day moving average is $57.86. The firm has a market capitalization of $73.03 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.08 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the company posted $0.75 EPS. Boston Scientific’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a share repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.